The Effects of Combined Use of Ovarian Needle Puncture and Platelets Rich Plasma on Ovarian Total Antioxidants Capacity (TAC) Level and ICSI Outcome in PCOS Women
Downloads
Background: Hyperandrogenism, ovulatory dysfunction, abnormal GnRH pulsation leading to irregular gonadotropin secretion all contribute to PCOS. Platelet Rich Plasma (PRP) are increasingly used for various disorders, including infertility, and is effective for ovarian rejuvenation via improving folliculogenesis.
Objectives: To estimate the effects of combined use of Ovarian Needle Puncture and PRP on ovarian total antioxidant capacity and ICSI cycle characteristics and outcome in PCOS Women
Patients and Methods: This study involved seventy women of infertile couples; patients were randomly allocated into two groups: PRP Group (35 women): Patients who underwent simultaneous use of Ultrasound-guided trans-vaginal ovarian needle puncture and PRP in the preceding cycle of ICSI cycle. Non PRP Group (35 women): Patients who didn’t undergo simultaneous use of Ultrasound-guided trans-vaginal ovarian needle puncture and PRP in the preceding cycle of ICSI cycle. CD7-CD8: Ultrasound-guided trans-vaginal ovarian needle puncture coincided with ovarian PRP was done under general light anesthesia for PRP group. Total antioxidant capacity was measured in the follicular fluid collected on the day of oocyte retrieval.
Results: There were no notable differences between PRP and Non-PRP groups in stimulation, oocyte, embryo characteristics, or ovarian total antioxidant capacity levels on ova pick up- day. Pregnancy rates were higher in the PRP group for both fresh (34.3% vs 20.0%, P < 0.113) and frozen ET (20.0% vs 14.3%, P < 0.292), though not statistically significant.
Conclusion: Although the combined use of ovarian needle puncture and platelet-rich plasma (PRP) did not produce significant effects on ovarian total antioxidant capacity (TAC) levels or on oocyte and embryo yield in women with PCOS, the cumulative pregnancy rate was higher following this intervention. These findings suggest the need for further large-scale studies to confirm the potential benefits of this approach.
1. WHO
2. Aversa, A., La Vignera, S., Rago, R., Gambineri, A., Nappi, R.E., Calogero, A.E. and Ferlin, A. (2020). Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Frontiers in Endocrinology, 11(516). doi:https://doi.org/10.3389/fendo.2020.00516.
3. Żeber‐Lubecka, N., Michał Ciebiera and Hennig, E.E. (2023). Polycystic Ovary Syndrome and Oxidative Stress—From Bench to Bedside. International Journal of Molecular Sciences, 24(18), pp.1412614126 https://doi.org/10.3390/ijms241814126
4. Li, W., Liu, C., Yang, Q., Zhou, Y., Liu, M. and Shan, H. (2022). Oxidative stress and antioxidant imbalance in ovulation disorder in patients with polycystic ovary syndrome. Frontiers in Nutrition, 9. https://doi.org/10.3389/fnut.2022.1018674
5. Cheng, X. and He, B. (2022). Clinical and Biochemical Potential of Antioxidants in Treating Polycystic Ovary Syndrome. International Journal of Women’s Health, [online] Volume 14, pp.467–479. DOI: 10.2147/IJWH.S345853
6. Rudnicka, E., Duszewska, A.M., Kucharski, M., Tyczyński, P. and Smolarczyk, R. (2022). Oxidative stress in polycystic ovary syndrome (PCOS). Reproduction, 164(6). DOI: https://doi.org/10.1530/REP-22-0152
7. Lee, C.-H., Lee, C.-Y., You, H.-L., Wu, Y.-T. and Chen, D.-P. (2024). The growth factor content as an indicator of platelet counts in platelet-rich plasma. Clinica Chimica Acta, 564, pp.119901–119901. doi:https://doi.org/10.1016/j.cca.2024.119901
8. Tambeli, C.H. (2023). Platelet-rich plasma in pain management. Nanotechnology and Regenerative Medicine, [online] pp.397–409. doi:https://doi.org/10.1016/b978-0-323-90471-1.00016-5.
9. Zhang, J., Tang, L., Kong, L., Wu, T., Xu, L., Pan, X., et al. (2021). Ultrasound-guided transvaginal ovarian needle drilling for clomiphene-resistant polycystic ovarian syndrome in subfertile women. The Cochrane database of systematic reviews, 11(11), CD008583. https://doi.org/10.1002/14651858.CD008583.pub3
10. Sánchez, M., Beitia, M., Pompei, O., Jorquera, C., Pello Sánchez, Knörr, J., Soldado, F., López, L., Oraa, J., Ane Miren Bilbao, Nicolás Fiz, Guadilla, J., Aizpurua, B., Azofra, J. and Delgado, D. (2020). Isolation, Activation, and Mechanism of Action of Platelet-Rich Plasma and Its Applications for Joint Repair. IntechOpen eBooks. DOI: 10.5772/intechopen.90543.
11. Fraidakis, M., Giannakakis, G., Anifantaki, A., Skouradaki, M., Tsakoumi, P., Bitzopoulou, P., Kourpa, S., Zervakis, A. and Kakouri, P. (2023). Intraovarian Platelet-Rich Plasma Injections: Safety and Thoughts on Efficacy Based on a Single Centre Experience With 469 Women. Cureus. [online] doi:https://doi.org/10.7759/cureus.38674.
12. Merhi, Z., Seckin, S. and Mouanness, M. (2022). Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization. Clinical and Experimental Reproductive Medicine, 49(3), pp.210–214. doi: 10.5653/cerm.2021.05057.
13. Dashore, S., Chouhan, K., Nanda, S. and Sharma, A. (2021). Preparation of platelet-rich plasma: National IADVL PRP taskforce recommendations. Indian Dermatology Online Journal, 12(7), p.12. doi: 10.4103/idoj.idoj_269_21
14. Muhssin, S. and. AL-Anbari, L. (2022). Evaluation of LH Level at Different Time Points During the Follicular phase in ICSI Cycle and Correlation with Pregnancy. IraQi Journal of Embryos and Infertility Researches, 12(1), pp.37–54. doi:https://doi.org/10.28969/ijeir.v12.i1.r4.22.
15. Ashraf Alyasin, Shayesteh Mehdinejadiani and Ghasemi, M. (2016). GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. Iranian Journal of Reproductive Medicine, 14(9), pp.557–566. doi:https://doi.org/10.29252/ijrm.14.9.557.
16. Shrivastava, J., More, A., Shrivastava, V., Choudhary, N. and Shrivastava, D. (2024). Enhancement of Ovarian Reserve and Oocyte Quality After Platelet-Rich Plasma Instillation in a Woman With Diminished Anti-Müllerian Hormone. Cureus. [online] doi:https://doi.org/10.7759/cureus.53474
17. Kawamura, K., Cheng, Y., Suzuki, N., Deguchi, M., Sato, Y., Takae, et al. (2013). Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proceedings of the National Academy of Sciences, 110(43), 17474–17479. https://doi.org/10.1073/pnas.1312830110.
18. Xia, L. J. and Du, J. (2022). Mechanical stress-induced Hippo signaling in respect to primordial follicle development and polycystic ovary syndrome pathogenesis. Reproductive and Developmental Medicine, 6(2), 121–128. doi:https://doi.org/10.1097/rd9.0000000000000009
19. Zhu, M., Xu, M., Zhang, J. and Zheng, C. (2023). The role of Hippo pathway in ovarian development. Frontiers in Physiology, 14, 1198873. https://doi.org/10.3389/fphys.2023.1198873
20. Rubin, S. C., Noruzi, K., Chen, E., Greene, A., & Keltz, M. (2025). The combination of ovarian rejuvenation with platelet-rich plasma (PRP) and transvaginal ovarian drilling (tvod) increases the percent of euploid embryos per cycle in low prognosis ivf patients. Fertility and Sterility, 124(1), e44-e45. https://doi.org/10.1016/j.fertnstert.2025.05.065
21. Gusti, A.M.T., Qusti, S.Y., Alshammari, E.M., Toraih, E.A. and Fawzy, M.S. (2021). Antioxidants-Related Superoxide Dismutase (SOD), Catalase (CAT), Glutathione Peroxidase (GPX), Glutathione-S-Transferase (GST), and Nitric Oxide Synthase (NOS) Gene Variants Analysis in an Obese Population: A Preliminary Case-Control Study. Antioxidants, 10(4), p.595. doi:https://doi.org/10.3390/antiox10040595
22. Anvari, S.S., G Holamreza Dehgan and Razi, M. (2019). Preliminary Findings of Platelet-Rich Plasma-Induced Ameliorative Effect on Polycystic Ovarian Syndrome. DOAJ (DOAJ: Directory of Open Access Journals), 21(3), pp.243–252. doi:https://doi.org/10.22074/cellj.2019.5952
23. Mazloomi, S., Sanoeei Farimani, M., Tayebinia, H., Karimi, J., Amiri, I., Abbasi, E., et al. (2022). The Association of Mitochondrial Translocator Protein and Voltage-Dependent Anion Channel-1 in Granulosa Cells with Estradiol Levels and Presence of Immature Follicles in Polycystic Ovary Syndrome. Journal of reproduction & infertility, 23(3), 148–159. https://doi.org/10.18502/jri.v23i3.10005.
24. Chen, Y., Yang, J., & Zhang, L. (2023). The Impact of Follicular Fluid Oxidative Stress Levels on the Outcomes of Assisted Reproductive Therapy. Antioxidants (Basel, Switzerland), 12(12), 2117. https://doi.org/10.3390/antiox12122117
25. Guo, Z. and Kawamura, K. (2025). Ovarian Function Restoration Using Autologous Platelet‐Rich Plasma. Reproductive Medicine and Biology, 24(1). doi:https://doi.org/10.1002/rmb2.12666
26. Yahyavi, Y., Karimi, A., Ebrahimi-Kalan, A., Ramezani, F., Hasanzadeh, M., Yousefi, S., et al. (2024). Assessment of platelet-rich plasma (PRP) effects on the proliferation and apoptosis of cyclophosphamide-induced damage in human granulosa cells. Pharmaceutical Sciences, 30(2), 204-214. https://doi.org/10.34172/ps.2023.25
27. Belebecha, V., Casagrande, R., Urbano, M. R., Crespigio, J., Martinez, R. M., Vale, D. L., et al. (2020). Effect of the platelet-rich plasma covering of polypropylene mesh on oxidative stress, inflammation, and adhesions. International urogynecology journal, 31(1), 139–147. https://doi.org/10.1007/s00192-019-03938-5
28. Ma, Y., Xuan, M., Dong, Y., Wang, H., Huang, J., Cheng, B. and Cui, X. (2021). Platelet-rich plasma protects human melanocytes from oxidative stress and ameliorates melanogenesis induced by UVB irradiation. 85(7), pp.1686–1696. doi:https://doi.org/10.1093/bbb/zbab085.
29. Wani, F. A., Ibrahim, M. A., Ameen, S. H., Farage, A. E., Ali, Z. A., Saleh, K., et al. (2023). Platelet Rich Plasma and Adipose-Derived Mesenchymal Stem Cells Mitigate Methotrexate-Induced Nephrotoxicity in Rat via Nrf2/Pparγ/HO-1 and NF-Κb/Keap1/Caspase-3 Signaling Pathways: Oxidative Stress and Apoptosis Interplay. Toxics, 11(5), 398. https://doi.org/10.3390/toxics11050398
30. Su, L., Xie, S., Li, T., Jia, Y., & Wang, Y. (2024). Pretreatment with platelet-rich plasma protects against ischemia-reperfusion induced flap injury by deactivating the JAK/STAT pathway in mice. Molecular medicine (Cambridge, Mass.), 30(1), 18. https://doi.org/10.1186/s10020-024-00781-3
